Ozempic

We are very close to having a “ozempic in pill.” His main competitor has developed it

by

The success of drugs such as Ozempic, Wegovy either Zepbound He has unleashed a career in pharmaceutical laboratories around the world. These are based on compounds originally devised as treatments against type 2 diabetes but have devastated as weight loss formulas. Orforglipron. The American pharmaceutical has successfully overcome The third phase of your clinical trials. As the company explains, this formula is the first drug in its class to pass this test, the first oral agonist of LPG-1 receptors of a small molecule that can be consumed without restrictions on water or food consumption. GLP-1 agonist. Orforglipron, such as the semaglutida on which Ozempic and Wegovy are based, is an agonist of the peptide receptors similar to glucagon-1 (LPG-1), that is, it is based on a molecule that emulates this hormone that produces our body. LPG-1 is a peptide that is released in our body when we eat and transmits the message that we have eaten two recipients for two different purposes. On the one hand, this message transmits to the pancreas so that it begins to segregate the insulin that our body will require to metabolize the sugar consumed. Hence, this type of compound is used in patients with type 2 diabetes. The second message is transmitted to the brain, which interprets it as a feeling of satiety. Achieve The Achieve-1 trial, framed in the Achieve program, was carried out with the objective of evaluating the safety and efficacy of Orforglipron, contrasting its administration with the administration of a placebo in adults with type 2 diabetes and inappropriate glycemic control. The experiment also studied different dosages in the participants. The responsible team observed that, after 40 weeks, the average blood glucose levels They differ satisfactorily between the experimental group and the control group. The study also showed a reduction in the body mass of those who consumed the drug. “It is a pleasure to see that our last medicine (…) meets our expectations of safety and tolerability, glycemic control and weight loss, and we are waiting for additional readings of the data throughout this year,” indicated in a press release David A. Ricks, President and CEO of Lilly. The details of these clinical trials will be presented in the scientific sessions of the ADA (American Diabetes Association), as well as in a magazine in an article reviewed by pairs. Adverse effects. One of the most important purposes of clinical trials is the detection of possible adverse effects with which to evaluate whether the drug involves any important risk and if its possible adverse effects are compensated or not by their medical benefit. The side effects detected are not very different from those already found in treatments such as Ozempic. The most common adverse effects were gastrointestinal and “generally between soft and moderate in severity”: diarrhea, nausea, dyspepsia vomiting (indigestion or empacho) or constipation. Those responsible for the study indicated that no hepatic security problems were detected. A key step. Overcoming this third phase of clinical trials is a fundamental step for the arrival of the drug to pharmacies but does not imply its immediate approval. The final green light will have to give it the regulatory agencies of pharmacological products such as the US FDA or the European EMA. In Xataka | Ozempic will soon become a thing of the past: this is what we know about the new generation of drugs for weight loss Image | JESHOTS.com

We have a way to improve the effectiveness of treatments such as Ozempic to lose weight: deceive metabolism

by

Our body did not evolve for the vicissitudes of modern life. During a good part of human existence, staying alive required for example that our body reacts to food shortages to prevent our energy consumption from becoming excessive and drained our reserves. In the world the contemporary world, this strategy has become an inconvenience for many who want to lose weight. A new way. Now this can change thanks to a New discovery. A team of researchers has discovered a mechanism used by the liver in the consumption of sugars and fats. Although the finding is still limited to animal models, the team believes that it shows potential to help improve the effectiveness of weight reduction treatments and even against diabetes. Facing the deficit. Layout seems simple: we just have to spend more calories than we consume. However, this is often complicated, since our body is an expert manager of its energy economy, knows how to react to scarcity. When we see ourselves in a prolonged situation in which we reduce the energy contribution of our body, that is, we ingest less calories, our body reacts reducing our energy consumption. To do this, it has a key tool: slow down metabolism. This implies for example, that after a time of diet, we can see how the weight we lower is reduced. Something that even affects people who resort to drugs such as Ozempic and Wegovy or Zepbound. PLVAP. The team responsible for the finding, They explainHe was studying a gene called Plvap in mice hígados. This is also a gene present in human cells. It was known that people with mutations that eliminated this gene presented problems by metabolizing lipids (fats), which focused group interest. The study of this gene allowed to discover that its function It has to do with metabolic change that occurs when our body goes from consuming sugar to consume fats during fasting. If this gene is not activated, the body continues to burn sugar as if nothing happened. Deceive the body. Controlling this newly discovered mechanism would open the way to improve the treatments present for weight loss. The strategy to achieve this would be to use this gene to “deceive” the liver in its regulation of our metabolism. The details of the study were published In an article In the magazine Cell. Not just a matter of weight. Controlling our weight is something that arouses enormous interest, as the successes of drugs such as those belonging to the Ozempic family have demonstrated. However, those responsible for the study point out that they could also help us treat metabolic diseases. An example is diabetes due to the role of PLVAP protein in the way our body processes sugar. A long road ahead. Transforming the finding into a treatment that can reach people will take years. For now, work has only been carried out in mice, which implies that it must still be demonstrated that the same mechanisms operate in the metabolism of human beings, something predictable but for now without contrast. Designing a drug and getting all common controls, including clinical trials is also something that requires time and, above all effort. The success of the new generation of drugs for weight loss is at least an indication that this type of treatments is on the laboratory agenda, so the effort is. In Xataka | We have been trying to find out why we get fat. Science is increasingly clear Image | Xataka with Gemini / Andres Ayrton

We talked to the Spaniards who have tried the Russian mountain of Ozempic

by

After the media explosion of the so -called “medicines for diabetes that lose weight”, we have spoken with three people who carry approximately One year using semaglutida, the active substance of Ozempic and Wegovy (The brand launched by the Ozempic manufacturer for the general public), in order to know your real experience beyond noise. From 160 to 105 kilos: “It has been a change of life” Pilar, Alicantina, 65, began her treatment with Ozempic over a year by medical prescription. “I have a fairly considerable weight, I reached 160 kilos during the pandemic. My knees hurt, I went to the doctor and the endocrine advised me to try with Ozempic“He explains. The result was overwhelming: 55 kilos less in a year. “I lost a lot of weight, I had some times dizziness and that, but nothing out of the ordinary,” he says. After a year of treatment, Pilar left it and recovered 20 kilos, until reaching the current 125. Recently he tried to resume the treatment, but he has encountered two problems: on the one hand, “he has not sat as well as the first time”; On the other, “Ozempic is very scarce, the pharmacy does not give it to you.” Then we will go with the matter of shortages. Pilar points out that the drug radically changed its relationship with food: “When you take Ozempic you don’t have that anxiety you have when you don’t take it. It takes away the desire to eat sweets especially and processed products.” Jorge, 38 -year -old Andalusian, has been using Wegovy for months (the specific version for the weight control of the semaglutida) by private route. With a height of 1.79 cm, its initial weight was 95 kilos. It is currently at 85.7. “I started taking it because due to an injury I won in a period of three or four months about 12 kilos,” he explains. “To play sports again and be in a physical state similar to the one before the injury, the first thing I had to do was lose all that weight.” Unlike Pilar, who received his medicine for social security, Jorge agreed to him through a private specialist: “He made me analysis to verify that everything was in order, and we started with a dose of 0.25 mg, the pen of 0.25”. Its monthly cost is around 180-190 euros. Wegovy pen shown by Jorge. Ceded image. The side effects soon appeared: “I started noticing in the first food intake. I click the dose at 8 in the morning and already at noon food I noticed that it was hard for me to eat.” Jorge describes a constant feeling of satiety and even some rejection of food: “Meals with a lot of fat, with a lot of sugar, sauces, heavy carbohydrates … They were meals that did not feel well.” Clara, 36 years old and resident in Madrid, began using Ozempic thirteen months after several failed attempts with traditional diets. “I tried everything: oto, intermittent fastingcounting calories … I lost 3 or 4 kilos at most and then recovered them with interest, “he says. Starting from 87 kilos, he has managed to go down to 69. “The first month was a bit hard for the nausea, but then I got used to And now I barely have side effects, just some occasional constipation, “he explains. Unlike Jorge and Pilar, Clara obtained the medicine by an alternative route. “A diabetic relative gave me a pen to try and then I got the recipe through a doctor friend,” he admits. “I know it’s not right, but I was desperate.” For her, The most shocking thing has been the change in their eating habits: “It is as if someone had turned off a switch in my brain. I no longer constantly think of food, or obsess myself with chocolate or fried potatoes.” The expert’s voice: beyond the “insulin that thinns” The Dr. Alicia Taboadasubspecialized family doctor in cardiovascular risk and endocrinological diseases, clarifies: “Ozempic is not an insulin, as many people think. It is a LPG-1 (peptide similar to type 1 glucagon) that in principle was for the treatment of diabetes, but it was discovered that it had an effect on weight without affecting glucose levels.” As explained, these medications “They act delaying gastric emptying, which has a feeling of satietyalready cerebral level they take away that need to eat. “However, he warns:” This drug will help you lower weight, but if you do not change habits you will have rebound effect, because very few people can afford to be putting this drug all your life. “ The doctor has noticed an increase in consultations related to these medications: “has increased a lot. Many people want that ‘insulina’ that makes you lose weight. That is why Ozempic has ended in the market and diabetics have been affected. “ Side effects and relationship with food The three interviewees agree that they experienced side effects, especially at the beginning of treatment. “I had a little anguish, dizziness, a vomit once and headache,” says Pilar. “I went to the doctor, he told me it was normal.” Jorge describes a feeling of “rejection of food” and “discomfort if I exceeded me a little, like empacho.” Clara adds: “I got 24 hours without hunger, the body simply asked me.” Pilar’s Ozempic box. Ceded image. The relationship with food changes radically. “It takes away your desire to eat sweets and processed products,” explains Pilar. Jorge coincides: “The main effect is that it takes away your cravings, the typical craving of six in the afternoon of something sweet.” The three interviewees agree on The importance of combining exercise with exercise and food changes. “Totally,” says Pilar. “The endocrine tells you: if you get Ozempic and you don’t make a diet and don’t walk, it’s not the miracle.” Jorge has maintained an intense regime of exercise: “I have continued and resumed high intensity sport with six weekly training”, which has accelerated its weight loss: “The loss has been … Read more

If the alcohol industry no longer had enough problems, it has now encountered one more: Ozempic

by

The drugs of the family of the GLP-1 hormone (peptide similar to type 1 glucagon) as Ozempic or Zepbound have meant a revolution in the world pharmaceutical market. The success of these medications aimed at the treatment of diabetes has to do with its slimming effect but the ramifications of this phenomenon go further. New tests. One of these ramifications has to do with alcohol consumption: a new study He has found evidence That the semaglutida, the active compound used by drugs such as Ozempic or Wegovy, can also help in the treatment of alcohol addiction. Chronicle of a social phenomenon. Ozempic began to gain popularity about two years ago when it began to be used not to keep glycemic levels under control in people with type II diabetes, but as a treatment to lose weight both in people with diabetes and in those who only wanted to lose weight. In parallel, several clinical trials endorsed this effect and the regulatory organisms approved the use of the drug for this second use. This success led to the appearance of other side effects associated with this compound, some of them positive. It was then that some laboratories got to work to test these effects. Among them An apparent reduction in alcohol consumption among those who were under this treatment. How does it work? The GLP-1 hormone performs several functions in our body, one of them being indicating that we have satiated our appetite. That is why the drugs that function as their analogues in our body generate the same feeling of satiety, which in turn implies that we will eat less and therefore lose weight. But soon some users began to realize that this not only affected food, but also the alcohol they consumed. Although the mechanism is not entirely clear, it is possible to intuit that it is the same mechanisms that enter into operation. There is another factor to take into account, and among the Side effects From ozempic drugs we can find stomach symptoms such as nausea and vomiting. This can also lead to alcoholic beverages less appealing, as well as other foods. 48 participants. The study was conducted through a randomized rehearsal with placebo. That is to say, It was distributed randomly to the 48 participants in two groups: one was treated with semaglutida and another with a placebo. They contrasted that the effects of treatment were greater than those of a simple placebo, that is, the participants drank less alcohol. While the number of days in which the participants drank these were not reduced in less volume. “These data suggest the potential of the semaglutida and drugs similar to covering an existing need for treatment for alcohol use disorder,” explained in a press release Klara Klein, member of the study responsible for the study. “Broader studies (…) are necessary to fully understand security and efficacy in people with (this) disorder, but these initial results are promising.” The team presented the details of the essay In an article In the magazine Jama Psychiatry. The analyzes continue. The reduced sample size in this study suggests that there is still a lot of work to be done. If we want to better understand Ozempic’s potential to fight addictions and similar disorders will need experiments with greater samples and studies that allow us to better understand the underlying biological mechanisms, as well as the potential risks of this use. All this while other teams investigate other potential risks and benefits of this drug family. An example of the potential benefits still to explore is In cardiac healthcontext in which we have begun to see some potential benefits but that, as in the case of excessive alcohol consumption, we must still explore more thoroughly. In Xataka | In Tinder there is a trend that is gaining weight between generation Z: quotes without a single drop of alcohol Image | Andreas m / Chemist4u

The atlas of side effects (positive and negative) of Ozempic discovered | Health and well-being

by

All medications have side effects, just take a look at any leaflet to see this. But there are not many cases in which these amount to the main effect. This is what happened a few years ago with GLP-1 agonists, medications used for decades to treat type 2 diabetes that began to demonstrate weight-loss effects. After several reformulations, new commercial brands, such as Ozempic and Wegovy, became an effective way to end obesity. But science is proving that there are many other side effects that could become major ones. GLP-1 is a molecular Swiss army knife, a kind of all-purpose drug. They affect our bodies in ways we still don’t fully understand. But today we are closer to listing. A team of scientists from the University of Washington School of Medicine has published the first detailed atlas of the side effects of these drugs. They have found benefits for cognitive and behavioral health, while revealing an increased risk of developing pancreatitis and kidney conditions. “Until now we had seen anecdotes and reports here and there. “Some people saying that it can affect this or that,” explained its main author, the clinical epidemiologist, in the presentation of the study. Ziyad Al-Aly, from the John J. Cochran Veterans Hospital. “But no one, no one had thoroughly investigated the effectiveness and risks of GLP-1 and all the ways it can affect health.” The study was published this Monday in the journal Nature Medicineshowcase of the best world science. More information “We did an analysis that comprehensively mapped the associations between GLP-1 and 175 potential health effects,” Al-Aly notes. The benefits, beyond weight loss, included a lower risk of substance use disorders and a reduction in suicidal ideation, schizophrenia, and other psychotic disorders. They also observed a reduction in cognitive disorders, such as Alzheimer’s and dementia. And finally, a reduction in the risk of clotting disorders, including stroke. “We found that these drugs have a wide range of beneficial effects, but all this does not come without risks,” warns the expert. The study confirms that, in some cases, they can cause gastrointestinal problems, such as nausea and vomiting. This is quite common and has already been documented in some patients. An increased risk of gastroparesis or stomach paralysis in rare cases and an increased risk of low blood pressure have also been seen. The analysis also notes that the drug may increase the risk of sleep problems and headaches, kidney stones, and drug-induced kidney inflammation. For these reasons, the authors recommend that, when evaluating this treatment, it should always be done under medical supervision and after an individualized analysis. “It is an observational study, although it has a large database and has been carried out for a long time,” he explains. Christopher Moralesan endocrinologist at the Virgen Macarena University Hospital in Seville, who was not involved in the study. The study does not demonstrate, therefore, that the medication is the cause of the listed effects. But these are consistent enough (risk reduction between 10 and 20%) and the database large enough (almost two million patients over three years) to think there is a direct relationship. “With Big Data you can scrape these results in very large databases and this is positive. But we must remember that here we can only verify association, not causality.” The objective of this research, in the words of its own authors, was not to analyze a specific effect and demonstrate causality, but to build an atlas of the association of risks and benefits of this relatively new medicine. “It’s like when Christopher Columbus arrived in America, and he thought about mapping it to get his bearings,” explains Al-Aly. “This is what we are doing, drawing a landscape of benefits and risks.” This opens the door to the possibility that in the future, after many reformulations and research, we can talk about an Ozempic for dementia, alcoholism or Alzheimer’s. There is still a long way to go, but this study has drawn a first map to locate the path. And there are many companies willing to embark on this adventure. There is currently a scientific and commercial race to find the next revolutionary use of GLP-1 agonists. Everyone has in mind the case of Novo Nordisk, the Danish laboratory that presented Ozempic in 2018, and which today has a stock market capitalization of 382,000 million dollars, which makes it the largest company in Europe. This has enormous business and economic implications, but from the scientific world, the question is different. How does an anti-diabetes drug have so many and varied effects? “Medicines don’t work surgically. They are designed to do one thing, but the reality is that this is almost never the case,” reflects Al-Aly. “Biology is complex and multiple, and if you touch one thing you will create a network of various effects.” GLP-1 acts on the intestine, but also on the brain, affecting areas that are involved in impulse control and reward signaling. This would explain why they help mitigate addiction problems. These medications would also affect the blood vessels, and in doing so have a potential effect on the heart. There is research that suggests that they also reduce inflammation, including that of the brain, which could explain their protective effect against neurodegenerative diseases. “But there is also another simpler theory that can explain all these positive health effects,” explains Al-Aly. Obesity is considered a disease in itself, but also the gateway to many others. It is the fifth risk factor for death in the world and every year 2.8 million adults die as a result of this condition. “When we treat obesity, it is normal that this affects other diseases, since it is the mother of them all,” summarizes Al-Aly. The expert has not yet decided, with the available scientific evidence, on which of these two theories has more force. The first would mean that we are talking about a miracle drug with multiple uses. The second would be less profitable for companies, would fill … Read more

Johann Hari, journalist: “The idea that obesity is a sin is deeply rooted in our culture” | Health and well-being

by

A couple of days after starting to take Ozempicsays the journalist and writer Johann Hari (Glasgow, 46 years old), he woke up with a strange sensation, unknown to him: he was not hungry. He got out of bed and went out to have breakfast at the bar, the usual breakfast, a chicken sandwich with mayonnaise. He took a couple of bites and couldn’t finish it. It was full. The medicine, belonging to that generation of drugs that have revolutionized The fight against obesity by imitating the effect of a hormone (GLP-1) that tells us when we are full, was restoring a lost perception: that of satiety. Hari tells this and other anecdotes about his experience with these medications in his new book Lose weight at any price. How Ozempic and other drugs are going to revolutionize our diet and our physical and mental health (Península), which reaches bookstores today. In these pages, the journalist, who has been overweight since he was young, embarks on a journey, accompanied by obesity experts and scientists who have participated in the development of the new drugs, for the benefits and risks of these treatments, the uncertainties that surround them and the uncertain scenarios that open in the field of health and beyond it. The journalist attends EL PAÍS by videoconference from London. More information Ask. He has spoken to many scientists. What has impressed you the most about what they have told you? Answer. Which obesity it really does you. Since I was seven years old I knew that being overweight is not good for your health, but I was surprised by the evidence of how serious it is. If you are obese, you are much more likely to suffer a heart attack, stroke, dementia and cancer. If you are obese by the time you are 18, you are 70% more likely to develop type 2 diabetes. And diabetes is the leading preventable cause of blindness in the UK and limb amputation in the US. Q. He assures that these anti-obesity drugs are destined to be the defining medicine of our time, like birth control pills or Prozac at other times in the last century, for example. Why do you say it? R. Because obesity is the biggest cause of death in the Western world. And now we have a medicine that, if you take it, reverses it and puts an end to it. It’s amazing. So all of us who are overweight or obese have a choice, but we have to compare the risks of remaining obese with the risks of these medications and think about it a lot. (These drugs) They are going to have enormous effects. Q. How can they change our lives and our culture? R. The change is enormous. Jefferies Financial, which is a financial consulting firm, made a report for American airlines saying that they may have to spend much less money on jet fuel, because it costs more money to fly with heavier people and that is going to be a much smaller population. Also in Los Angeles there has been an increase in demand for jewelers to change and adjust wedding rings because people have lost so much weight that the rings no longer fit on their fingers. Approximately 20% of Americans have already tried these medications. This is huge. This is an astonishing scientific advance that will profoundly change society for better and worse. “The foods we eat are undermining our ability to feel full” Q. Regarding this negative part, he exposes some issues that the consumption of these medications entails, such as the risk of losing the culture of body positive or what would happen if people with eating disorders access these drugs that help them lose weight. Have you found answers to these questions? R. The invention of these drugs is like the discovery of fire. Fire is a great tool if I use it to heat my house, but it is terrible if I use it to burn my house down. And in the same way, when something as powerful as this is discovered, it will have great positive effects and great negative effects. If you are overweight or obese and start taking these medications, for example, you are 20% less likely to have a heart attack or stroke in the next 18 months. But you also mentioned something that worries me a lot: when you take these medications, you eat much less; and that’s good if you’re obese like me, but people with an eating disorderanorexia for example, if you are thin and start taking these medications, you can kill yourself with them. Therefore, one of the things we must do is regulate these medications very strictly. Q. The book also delves into what makes ultra-processed foods so addictive. Do they cause a kind of short circuit in our brain systems? R. If you look at a photograph of a beach in Spain in 1979, the year I was born, everyone is very thin and you wonder: where are the obese people? So, obesity was very low. Modern humans have been around for 300,000 years, but obesity was extremely rare. And basically, during my lifetime, it exploded. What happened? We know the answer: Obesity skyrockets everywhere people make a change, when they go from eating mostly fresh foods they prepared that day to eating primarily processed and ultra-processed foodsThat is, food is made up of chemicals in factories in a process that is not even called cooking, it is called making food. This new type of food affects us in very different ways. The foods we eat are undermining our ability to feel full and what these new medications do is restore the feeling of satiety. Q. And what about the industry’s responsibility in this context? R. Need regulate the food industry to prevent children from being exposed to these foods that make them sick and undermine their ability to feel full. I’m talking about a long-term solution and we … Read more

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.